Department of Obstetrics and Gynecology, Atrium Health, Charlotte, NC, United States of America.
Department of Orthopedic Surgery, Atrium Health Musculoskeletal Institute, Charlotte, NC, United States of America.
Gynecol Oncol. 2022 Sep;166(3):471-475. doi: 10.1016/j.ygyno.2022.06.020. Epub 2022 Jul 5.
Enhanced recovery after surgery (ERAS) has decreased hospital opioid use, but less attention has been directed towards its impact on clinic burden with respect to post-operative care. Our objective was to determine the impact of an ERAS protocol on post-operative opioid prescribing, and the subsequent number of pain medication refill requests and unscheduled patient-provider interactions in the 30-day post-operative period.
IRB-approved retrospective study comparing post-operative opioid prescription practices 10 months before and 10 months after ERAS protocol implementation after minimally invasive gynecologic surgery. Opioid doses in morphine milligram equivalents (MMEs), number of unscheduled visits, and phone calls were compared before and after ERAS implementation.
A total of 791 patients were included; 445 without and 346 with ERAS implementation. ERAS was associated with higher rates of same day discharge (49% vs 39%, p = 0.003) and lower readmission rates (2.0% vs 5.6%, p = 0.011). Post-operatively, patients who received the ERAS protocol were prescribed less opioids (197.8 vs. 223.5 MMEs, p = 0.0087). There was a trend towards less refill requests with ERAS (1.7% vs 3.6%, p = 0.11). ERAS was associated with a decreased number of post-operative phone calls (38% vs 46%, p = 0.023), including calls for pain (10% vs 16%, p = 0.021), and fewer unscheduled visits related to pain (1.5% vs 5.8%, p = 0.001).
Implementation of the ERAS protocol resulted in a decrease in post-operative opioid prescribing. Despite the lower amount of prescribed post-operative opioids, the ERAS protocol translated into a decrease in the need for post-operative interactions with the clinic staff, specifically encounters associated with pain.
手术加速康复(ERAS)减少了医院阿片类药物的使用,但对于术后护理方面,其对诊所负担的影响关注较少。我们的目的是确定 ERAS 方案对术后阿片类药物处方的影响,以及随后在术后 30 天内的止痛药续药请求和非计划性患者-提供者交互的数量。
经机构审查委员会批准的回顾性研究,比较微创妇科手术后 ERAS 方案实施前 10 个月和实施后 10 个月的术后阿片类药物处方实践。比较 ERAS 实施前后的吗啡毫克当量(MME)剂量、非计划性就诊和电话就诊数量。
共纳入 791 例患者;445 例无 ERAS 实施,346 例有 ERAS 实施。与 ERAS 相关的当天出院率较高(49%比 39%,p=0.003),再入院率较低(2.0%比 5.6%,p=0.011)。术后,接受 ERAS 方案的患者开具的阿片类药物较少(197.8 比 223.5 MME,p=0.0087)。有 ERAS 时续药请求的趋势较低(1.7%比 3.6%,p=0.11)。ERAS 与术后电话就诊次数减少相关(38%比 46%,p=0.023),包括因疼痛的电话就诊(10%比 16%,p=0.021)和因疼痛相关的非计划性就诊减少(1.5%比 5.8%,p=0.001)。
实施 ERAS 方案导致术后阿片类药物处方减少。尽管术后开具的阿片类药物较少,但 ERAS 方案减少了与诊所工作人员的术后互动需求,特别是与疼痛相关的就诊。